1-17 of 17
Kyle Zacholski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 4269.
https://doi.org/10.1182/blood-2023-189184
Published: 2023
Journal Articles

Revisiting Ratify: Daunorubicin 60 Mg/m 2 Vs 90 Mg/m 2 in Previously Untreated FLT3 mut Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5912.
https://doi.org/10.1182/blood-2023-189138
Published: 2023
Journal Articles

Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5093.
https://doi.org/10.1182/blood-2023-189322
Published: 2023
Journal Articles

CUX1 mut Acute Myeloid Leukemia As a Distinct Biological Entity: An Analysis of Clinical Outcomes and Implications

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5978.
https://doi.org/10.1182/blood-2023-189407
Published: 2023
Journal Articles

FLT3 Inhibitors in Combination with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5920.
https://doi.org/10.1182/blood-2023-188333
Published: 2023
Journal Articles

The Molecular Landscape of Acute Myeloid Leukemia with Trisomy 8: A Comprehensive Cancer Center Analysis of 627 Patients

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 6053.
https://doi.org/10.1182/blood-2023-189260
Published: 2023
Journal Articles

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH -Mutated AML

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 1488.
https://doi.org/10.1182/blood-2023-188400
Published: 2023
Journal Articles

Comparison of Response and Survival with Chemotherapy and Targeted Therapies between IDH mut Isoforms in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 6010.
https://doi.org/10.1182/blood-2023-188362
Published: 2023
Journal Articles

The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 4233.
https://doi.org/10.1182/blood-2023-188249
Published: 2023
Journal Articles

Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 13305–13306.
https://doi.org/10.1182/blood-2022-171223
Published: 2022
Journal Articles

Back in JAK - Real-World Analysis of JAK mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11812–11813.
https://doi.org/10.1182/blood-2022-171165
Published: 2022
Journal Articles

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11842–11843.
https://doi.org/10.1182/blood-2022-170972
Published: 2022
Journal Articles

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 5281–5282.
https://doi.org/10.1182/blood-2022-171063
Published: 2022
Journal Articles

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11745–11746.
https://doi.org/10.1182/blood-2022-171129
Published: 2022
Journal Articles

Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11744.
https://doi.org/10.1182/blood-2022-171018
Published: 2022
Journal Articles

Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 11742–11743.
https://doi.org/10.1182/blood-2022-170836
Published: 2022
Journal Articles

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher
Journal: Blood
Blood (2022) 140 (Supplement 1): 6335–6336.
https://doi.org/10.1182/blood-2022-170907
Published: 2022